Pennsylvania still trying get a slice of J&J Risperdal payouts
PA alleges that J&J oversold the drug's benefits while underselling the risks.
NIH taps Genentech drug for pioneering Alzheimer's study
Researchers will test crenezumab in Colombians with a particular genetic mutation, aiming to see if the drug can stop Alzheimer's before it starts.
Pfizer's Torisel fails to best Nexavar in trial; Merck KGaA's Erbitux lacks as an add-on to chemo, study says;
Pfizer To Present New Data In Advanced Kidney, Lung And Hematologic Cancers At 2012 ASCO Annual Meeting
Genentech Will Report New Data on Important Progress for People with Advanced Cancers at ASCO 2012
ASCO data to shine new light on Pfizer, Roche, J&J drugs
Cancer drug aficionados, rejoice. A slew of new studies goes public later today, as drugmakers gear up for next month's American Society of Clinical Oncology meeting.
Ex-BMS exec finishes book, and sentence, in conviction
A former Bristol-Myers Squibb executive has completed his sentence with a book on the Plavix scandal.
U.K. report says NICE drags its feet on drug approvals
British media are reporting on a study suggesting that U.K. patients twiddle their thumbs for up to 9 years as the National Institute for Health and Clinical Excellence deliberates over new products.
Revised patient access scheme and more information allow NICE to recommend abiraterone for prostate cancer
New discount persuades NICE to bless J&J's Zytiga
Britain's cost-effectiveness watchdog reversed its decision against the Johnson & Johnson prostate cancer pill, thanks to the company's new discount offer.
Latest Commentary